The Conversation (0)
Neuralstem Inc (NYSE MKT:CUR) provided its 2012 financial results and clinical trial program updates.
Neuralstem Inc (NYSE MKT:CUR) provided its 2012 financial results and clinical trial program updates.
As quoted in the press release:
A highlight of 2012 was the completion of our ground-breaking ALS Phase I trial. Following the last treatment of the final cervical cohort of return patients in August, our collaborators, University of Michigan’s Dr. Eva Feldman and Emory University’s Dr. Jonathan Glass , presented trial data that showed promise of a treatment effect for ambulatory ALS patients as well as definitive DNA-fingerprint evidence of long-term NSI-566 cell survival,” continued Dr. Johe.
Click here to read the full Neuralstem Inc (NYSE MKT:CUR) press release.